Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms

被引：36

作者：

Schiavi, Michele Carlo ^{[1
]}

Zullo, Marzio Angelo ^{[2
]}

Faiano, Pierangelo ^{[1
]}

D'Oria, Ottavia ^{[1
]}

Prata, Giovanni ^{[1
]}

Colagiovanni, Vanessa ^{[1
]}

Giannini, Andrea ^{[1
]}

Di Tucci, Chiara ^{[1
]}

Perniola, Giorgia ^{[1
]}

Di Donato, Violante ^{[1
]}

Monti, Marco ^{[1
]}

Muzii, Ludovico ^{[1
]}

Panici, Pierluigi Benedetti ^{[1
]}

机构：

[1] Univ Rome Sapienza, Umberto Hosp 1, Dept Gynecol & Obstet Sci & Urol Sci, Viale Policlin 155, I-00161 Rome, Italy

[2] Univ Rome, Campus Biomed, Dept Surg Week Surg, Rome, Italy

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 2017年 / 33卷 / 12期

关键词：

Menopause; ospemifene; overactive bladder; urodynamic testing; vulvovaginal atrophy; ESTROGEN-RECEPTOR MODULATOR; POSTMENOPAUSAL WOMEN; GENITOURINARY SYNDROME; DYSPAREUNIA; EFFICACY; HEALTH;

D O I：

10.1080/09513590.2017.1323859

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aims: The aim of this study was to assess the effectiveness and safety of ospemifene in the improvement of overactive bladder (OAB) symptoms in postmenopausal women affected by vulvovaginal atrophy (VVA).Methods: Forty-six postmenopausal patients affected by VVA with OAB syndrome were enrolled for the study. All patients received Ospemifene 60mg for 12weeks. Clinical examination, 3-day voiding diary, urodynamic testing, ultrasound measurement of endometrial and bladder wall thickness (BWT) and the Vaginal Health Index (VHI) were performed at baseline and 12weeks. Patients completed the OAB-Q SF and UDI-6.Results: After 12-weeks, the number of patients with detrusor overactivity decreased from 39% to 13% (p=0.04). The reduction in the mean number in 24h of voids (9.572.12 vs. 6.631.22, p<0.0001), urgent micturition episodes/24h (5.631.46 vs. 1.441.31, p<0.0001), nocturia episodes (3.170.85 vs. 1.11 +/- 1.18, p<0.0001), urinary incontinence episodes/24h (0.85 +/- 0.96 vs. 0.33 +/- 0.64, p=0.003) was observed. The UDI-6, OAB-Q symptoms, OAB-Q (HRQL) scores were 8.95 +/- 0.91 vs. 5.56 +/- 1.40, 62.60 +/- 14.70 vs. 20.08 +/- 10.83 and 18.71 +/- 7.41 vs. 79.45 +/- 14.47 (p<0.001) before and after 12weeks.Conclusion: Ospemifene is an effective potential therapy for postmenopausal women with VVA improving OAB symptoms and quality of life.

引用

页码：942 / 945

页数：4

共 30 条

[1] Combined Vaginal Pelvic Floor Electrical Stimulation (PFS) and Local Vaginal Estrogen for Treatment of Overactive Bladder (OAB) in Perimenopausal Females. Randomized Controlled Trial (RCT) [J].

Abdelbary, Ahmed Mahmoud ;

El-Dessoukey, A. Aref ;

Massoud, Amr M. ;

Moussa, Ayman S. ;

Zayed, Ahmed S. ;

Elsheikh, Mohame G. ;

Ghoneima, Waleed ;

Abdella, Rana ;

Yousef, Mohamed .

UROLOGY, 2015, 86 (03) :482-486

[2] Antimuscarinics for treatment of overactive bladder [J].

Andersson, KE .

LANCET NEUROLOGY, 2004, 3 (01) :46-53

[3]

Archer DF, 2015, MENOPAUSE, V22, P786, DOI 10.1097/GME.0000000000000365

[4] Urogenital ageing: An old problem newly recognized [J].

Bachmann, G .

MATURITAS, 1995, 22 :S1-S5

[5] Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study [J].

Bachmann, Gloria A. ;

Komi, Janne O. .

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2010, 17 (03) :480-486

[6] Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause [J].

Bondi, Chiara ;

Ferrero, Simone ;

Scala, Carolina ;

Tafi, Emanuela ;

Racca, Annalisa ;

Venturini, Pier Luigi ;

Maggiore, Umberto Leone Roberti .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (10) :1233-1246

[7] Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial [J].

Constantine, G. ;

Graham, S. ;

Portman, D. J. ;

Rosen, R. C. ;

Kingsberg, S. A. .

CLIMACTERIC, 2015, 18 (02) :226-232

[8]

Coyne K, 2000, VALUE HEALTH, V3, P141, DOI DOI 10.1016/S1098-3015(11)70554-X

[9] Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy [J].

Goldstein, S. R. ;

Bachmann, G. A. ;

Koninckx, P. R. ;

Lin, V. H. ;

Portman, D. J. ;

Ylikorkala, O. .

CLIMACTERIC, 2014, 17 (02) :173-182

[10] Local oestrogen for vaginal atrophy in postmenopausal women [J].

Lethaby, Anne ;

Ayeleke, Reuben Olugbenga ;

Roberts, Helen .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (08)

← 1 2 3 →